Epithelial Ovarian Cancer (EOC) is a malignant cancer with high mortality among Indonesian women. EOC showed no specific symptoms in its early stages, thus making the screening mostly occur when patients are in advanced stage. Treatment of advance-stage EOC is more challenging and prognosis is poor. Therefore, minimally-invasive biomarkers are needed to diagnose at the early stage. microRNA is one of the potential biomarkers which not only expressed inside the cell, but also secreted outside the cell with exosome protection. This protection makes microRNA stable. Moreover, several studies have shown the ability to detect microRNA in the blood sample. microRNA-21 (miR-21) is oncomiR targeting tumor suppressor mRNA RECK based on in-silico analysis. The first aim of this study is to determine the expression of miR-21 in plasma samples of EOC patients compared to healthy controls. The second aim is to investigate the expression correlation between miR-21 and RECK mRNA. Blood samples were collected from 30 patients and 30 healthy controls. Plasma was then obtained from centrifuged blood samples. The total RNA was isolated and reverse transcribed to produce cDNAs. cDNAs were then quantified using qPCR using specific primer for miR-21 and RECK mRNA. The expression analysis
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